Skip to main content
森萱医药 logo

森萱医药 — Investor Relations & Filings

Ticker · 920946 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2023-10-26 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920946

About 森萱医药

https://www.senxuan.cn/

Jiangsu Senxuan Pharmaceutical Co., Ltd. specializes in the research, development, and production of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and specialized fine chemicals. The company’s product portfolio includes key intermediates for antiviral medications, such as those used in the treatment of HIV, and anticonvulsant agents like Primidone. Additionally, it produces high-purity chemical solvents including 1,4-dioxane and 1,3-dioxolane for diverse industrial applications. Senxuan Pharmaceutical maintains a focus on advanced chemical synthesis and large-scale manufacturing capabilities, adhering to international quality standards to support the global life sciences and chemical sectors. Its operations are characterized by a commitment to technical innovation and the supply of critical chemical building blocks for complex therapeutic formulations.

Recent filings

Filing Released Lang Actions
第三届董事会第二十二次会议决议
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 22nd meeting of the 3rd Board of Directors of Jiangsu Senxuan Pharmaceutical Co., Ltd. It includes details about the meeting date, attendance, and voting results on several agenda items such as the approval of the 2023 Q3 report, reappointment of the accounting firm, and convening a shareholders' meeting. The document does not contain the actual quarterly report or financial data but references the 2023 Q3 report published separately (announcement 2023-054). The document is primarily a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is short (1626 characters), and it is not the report itself but an announcement of board decisions.
2023-10-26 Chinese
关于接待机构投资者调研情况的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Jiangsu Senxuan Pharmaceutical Co., Ltd. about a recent investor research meeting held on September 13, 2023. It includes a Q&A format discussing the company's half-year operating results, business outlook, product lines, market conditions, and strategic plans. The text references the company's half-year report but does not contain the full financial statements or comprehensive financial data itself. The document is relatively short (2947 characters) and serves as a summary of the investor meeting rather than a full interim or annual report. It is not a transcript of a conference call but a formal announcement of the investor research session and company responses. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-09-13 Chinese
关于接待机构投资者调研情况的公告
Investor Presentation Classification · 90% confidence The document is a detailed announcement about the company's reception of institutional investor research on September 13, 2023. It includes a Q&A format discussing the company's half-year operating results, product lines, market conditions, and future plans. The text references the company's half-year report published at the end of August but does not contain the actual financial statements or comprehensive financial data itself. The document is a communication of investor relations activity, specifically a summary of an investor research meeting and company responses to questions. It is not a full financial report, earnings release, or regulatory filing. Given the nature of the content as a summary of investor Q&A and company replies, it best fits the category of Investor Presentation (IP), which includes detailed presentations or communications for investors focusing on financials, strategy, and market position.
2023-09-13 Chinese
关于接待机构投资者调研情况的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the reception of institutional investor research on September 12, 2023. It includes a Q&A format discussing the company's half-year operating results, product lines, market outlook, and customer base. The document references the half-year report but does not contain the full financial statements or detailed financial analysis itself. The length is short (1980 characters), and the content is primarily a summary of investor questions and company responses rather than a formal financial report. Therefore, it is not an Interim/Quarterly Report (IR) or Annual Report (10-K). It is also not a Call Transcript (CT) since it is a written Q&A, not a conference call transcript. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about investor relations activities and company responses to investor inquiries, which do not fit other specific categories.
2023-09-11 Chinese
关于接待机构投资者调研情况的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the reception of institutional investor research inquiries and the company's responses. It includes a Q&A format discussing the company's half-year operating results, product lines, market outlook, and customer base. The document references the company's half-year report but does not contain the report itself or detailed financial statements. The length is short (1980 characters), and the content is focused on investor relations and company updates rather than a formal financial report. Therefore, it is best classified as a Regulatory Filing (RNS), as it is a general regulatory announcement and does not fit into other specific categories like Interim Report or Earnings Release.
2023-09-11 Chinese
2023年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "半年度报告摘要" which translates to "Half-Year Report Summary" for the year 2023. It contains detailed financial data such as total assets, net profit, revenue, earnings per share, and other financial metrics for the half-year period. It also includes company business descriptions, shareholder information, and notes on asset pledges and restrictions. The document is comprehensive and contains substantive financial data and analysis for a period shorter than a full fiscal year, which fits the definition of an Interim / Quarterly Report (IR). The document length is 4528 characters, which is sufficient to contain actual financial data rather than just an announcement. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2023
2023-08-24 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.